Healthcare Industry News: Millennium
News Release - February 10, 2009
Dilon Technologies Leads Molecular Breast Imaging ExpansionClinicians Embrace MBI Technique Breast-Specific Gamma Imaging (BSGI), Resulting in Record 2008 Sales
NEWPORT NEWS, Va., Feb. 10 -- (Healthcare Sales & Marketing Network) -- Dilon Technologies, Inc., a leader in molecular breast imaging, today announced record sales for 2008 highlighted by the strongest fourth quarter in the company's history. The company achieved a 35 percent increase in sales from 2007 to 2008 as molecular breast imaging gains nationwide exposure and acceptance.
Breast-Specific Gamma Imaging (BSGI) - a molecular imaging procedure, along with breast MRI, are expected to increase at a compound growth rate of 28 percent over the next five years, according to the Millennium Research Group's U.S. Markets for Women's Health Imaging Systems report. It also states that Dilon Technologies is leading the way to global availability of molecular breast imaging. Dilon's cornerstone product, the Dilon 6800 Gamma Camera is a high-resolution, compact gamma camera optimized to perform BSGI.
"We had a particularly strong finish to the year, breaking through a monthly sales record in December," said Bob Moussa, President and CEO of Dilon Technologies. "Breast imaging centers across the country and around the world are using BSGI to pave the way to effective diagnosis of breast cancer."
BSGI is an adjunctive molecular breast imaging technique to mammography that can see lesions independent of tissue density and discover early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image.
Dilon's molecular imaging technology is already available in Europe, parts of the Asian-Pacific basin, the Caribbean, and soon to be in Latin America. In addition, Dilon continues to pursue new alliances with companies such as Terason (Terason t3000(TM) Ultrasound System) and PenRad (PenRad Mammography Information System) to help deliver advanced diagnostic solutions to doctors and patients.
"BSGI and our expanded product and service offerings provide critical diagnostic information for physicians to diagnose and treat patients," said Moussa. "More than 50,000 patients have been imaged with BSGI. As we move forward into 2009, we will continue the momentum with the help of physicians worldwide."
About Dilon Technologies
Dilon Technologies, Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit www.dilon.com.
Source: Dilon Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.